Common Stock, par value $0.0001 per share
- Symbol
- CERO
- Exchange
- Not supplied
- Classification
- COMMON
Current Report · Items 8.01, 9.01 · 8-K
CERo Therapeutics Holdings, Inc.
Other Events
Item 8.01 Other Information. CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), has prepared a poster presentation that will be presented at the Transplantation and Cellular Therapy Meetings beginning on February 4, 2026. The poster presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K.…
Company context
CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering integrates key functional attributes of both innate and adaptive immunity within a single therapeutic construct, designed to engage the body’s immune repertoire for more comprehensive tumor targeting. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells toward tumor cells through both adaptive perforin/granzyme pathways and innate engulfment mechanisms, including targeting of the TIM-4 ligand. This employs phagocytic activity to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells (“CER-T”). CERo believes the differentiated targeting properties of CER-T cells may offer advantages compared with currently approved CAR-T therapies and could potentially extend the reach of cellular immunotherapy to both hematologic malignancies and solid tumors. CERo has initiated clinical trials for its lead product candidate, CER-1236, for hematologic malignancies.
Current securities
Historical securities (7)
CERONASDAQ · EQUITY · Historical · closed Oct 30, 2025CEROOTC · EQUITY · Historical · closed Oct 19, 2026CEROWNASDAQ · WARRANT · Historical · closed Oct 30, 2025CEROWOTC · WARRANT · Historical · closed Oct 19, 2026PBAXNASDAQ · EQUITY · Historical · closed Feb 14, 2024PBAXUNASDAQ · UNIT · Historical · closed Feb 14, 2024PBAXWNASDAQ · WARRANT · Historical · closed Feb 14, 2024
Recent company filings
- Entry into a Material Definitive AgreementOct 7, 2026
- Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity SecuritiesAug 31, 2026
- 424B3 filingAug 14, 2026
- 10-Q filingAug 14, 2026
- SCHEDULE 13G/A - filed by Tibbs Isaiah regarding CERO THERAPEUTICS HOLDINGS, INC.Aug 14, 2026
Registered securities in this filing
CERO THERAPEUTICS HOLDINGS, INC. · 8-K · Filed 2026-02-04
Warrants, each warrant exercisable for one two-thousandths of a share of Common Stock
- Symbol
- CEROW
- Exchange
- Not supplied
- Classification
- WARRANT
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Information.
CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”),
has prepared a poster presentation that will be presented at the Transplantation and Cellular Therapy Meetings beginning on February 4,
2026. The poster presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in the poster presentation is summary information
that should be considered within the context of the Company’s filings with the Securities and Exchange Commission and other public
announcements that the Company may make by press release or otherwise from time to time. The poster presentation speaks as of the date
of this Current Report on Form 8-K. While the Company may elect to update the poster presentation in the future or reflect events and
circumstances occurring or existing after the date of this Current Report on Form 8-K, the Company specifically disclaims any obligation
to do so.
Filed exhibits (1)
Exhibit 99.1 CER - 1236 is a first - in - class chimeric antigen receptor T - cell (CAR - T) therapy designed to induce phagocytic target clearance through a TIM - 4 - based receptor ectodomain. TIM - 4 targets TIM - 4 - L, or phosphatidylserine, a structural phospholipid expressed on apoptotic and cancerous cells, especially acute myeloid leukemia, but absent on healthy cells. TIM - 4 binding to its ligand results in both cytotoxic T cell killing and phagocytosis of target cells. This non - canonical mechanism differs from cytotoxic CAR - T approaches and is intended to modulate target clearance with reduced systemic inflammatory toxicity. We report the first - in - human clinical experience with CER - 1236 in advanced myeloid malignancies. INTRODUCTION ϙϙϙϙϙϙϙϙ First - In - Human Clinical Experience with CER - 1236, a First - In - Class TIM - 4 - Based Phagocytic CAR - T Therapy, Including Platelet Transfusion Independence In an Index Patient with High - Risk MDS/AML (inv(3)/Mecom) 5(68/76 Preclinical safety results reveal no off - tumor cytotoxicity Figure 3. (A) CER - 1236 response to healthy primary human cells was assessed by co - culturing CER - 1236 T cells with primary hu…
Open exhibit ↗